Niagen Bioscience Inc NAGE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
-
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
-
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
-
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
-
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
-
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
-
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
-
Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
Trading Information
- Previous Close Price
- $2.58
- Day Range
- $2.46–2.59
- 52-Week Range
- $2.46–7.95
- Bid/Ask
- $2.42 / $2.58
- Shares Outstanding
- 79.13M
- Market Cap
- $197.02M
- Volume/Avg
- 556,107 / 560,856
Key Statistics
- Price/Earnings (Normalized)
- 14.29
- Price/Sales
- 1.69
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.13%
Company Profile
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Stock Style Box
- Small Growth
- Total Number of Employees
- 117
- Website
- https://www.niagenbioscience.com
Valuation
|
Metric
|
NAGE
|
|---|---|
Price/Earnings (Normalized) | 14.29 |
Price/Book Value | 2.47 |
Price/Sales | 1.69 |
Price/Cash Flow | 12.02 |
Price/Earnings
NAGE
Financial Strength
|
Metric
|
NAGE
|
|---|---|
Quick Ratio | 5.00 |
Current Ratio | 6.50 |
Interest Coverage | — |
Quick Ratio
NAGE
Profitability
|
Metric
|
NAGE
|
|---|---|
Return on Assets (Normalized) | 11.31% |
Return on Equity (Normalized) | 15.54% |
Return on Invested Capital (Normalized) | 12.73% |
Return on Assets
NAGE
Packaged Foods Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Nestle SA ADR
NSRGY
| LOCK|N$>RfS | LOCK|@^ | $256B | |||
| Danone SA ADR
DANOY
| LOCK|y?JSr<> | LOCK|Lr&f | $44B | |||
| The Kraft Heinz Co
KHC
| LOCK|Xm>@sR | LOCK|r&^K | $28B | |||
| General Mills Inc
GIS
| LOCK|Hlm@@s | LOCK|@^G>$ | $18B | |||
| JM Smucker Co
SJM
| LOCK|!V | LOCK|Wt | $14B | |||
| McCormick & Co Inc Ordinary Shares (Non Voting)
MKC
| LOCK|cT<QX&# | LOCK|M< | $12B | |||
| The Magnum Ice Cream Co NV
MICC
| LOCK|tvb$Gz | LOCK|t? | $11B | |||
| Hormel Foods Corp
HRL
| LOCK|<T!H>>g | LOCK|P!rlK | $11B | |||
| Lamb Weston Holdings Inc
LW
| LOCK|^F | LOCK|F?B&z | $7B | |||
| Ingredion Inc
INGR
| LOCK|x#R%n!& | LOCK|!@m&< | $6B |
United States